$ALUR News

Last published 4mo ago

4mo agoALURAllurion Advances Plan to Re-ListBusiness WireAllurion Technologies, Inc. (OTCQB:ALUR), a pioneer in metabolically healthy weight loss, today announced a 1-for-15 reverse stock of its outstanding common stock intended to support regaining compliance with the
5mo agoALURAllurion Announces Strong Start to U.S. Launch with Exceptional Early Outcomes and Growth MomentumBusiness WireAllurion Technologies, Inc. (OTCQB:ALUR), a pioneer in metabolically healthy weight loss, today announced successful early traction in the launch of the Allurion Program in the United States, marked by strong clinical
8mo agoALURAllurion Intends to Appeal NYSE Notice of Delisting, Execute Plan to Regain Compliance, and Expects to Continue Trading on NYSEBusiness WireCompany's recent FDA approval catalyzes plan to regain compliance with listing requirements of NYSE or another exchange; shares of common stock expected to continue trading on NYSE during appeal process Allurion
8mo agoALURAllurion Announces Exercise of Warrants for $3.0 Million in Gross ProceedsBusiness WireAllurion Technologies, Inc. (NYSE:ALUR) (the "Company" or "Allurion"), a pioneer in metabolically healthy weight loss, today announced the entry into a definitive agreement for the immediate exercise of certain
8mo agoALURAllurion Receives U.S. FDA ApprovalBusiness WireApproval provides Allurion with access to approximately 80 million Americans with obesity Allurion Technologies, Inc. (NYSE:ALUR), a pioneer in metabolically healthy weight loss, today announced that the U.S. Food and
9mo agoALURAllurion Announces Partnership to Offer Combination Therapy with Mounjaro® (tirzepatide) at Discounted PricesBusiness WireThrough Bionut, a leader in obesity care in Argentina, Allurion Program patients will now have access to discounted Mounjaro to be used in combination with the Allurion Smart Capsule Allurion Technologies, Inc.
11mo agoALURAllurion Announces Initial Results on Combining the Allurion Program With Low-Dose Tirzepatide to Optimize Muscle Mass and GLP-1 AdherenceBusiness WireAverage Total Weight Loss of 23% With 14% Increase in Lean Body Mass After 12 Months All patients remained adherent to tirzepatide for the duration of the study Allurion Technologies, Inc. ("Allurion" or the
11mo agoALURNew Peer-Reviewed Publication Demonstrates Superior Weight Loss and Improved Body Composition with the Allurion Smart Capsule Combined with Lifestyle Intervention Compared to Lifestyle Intervention AloneBusiness WireCase-controlled study in 1,143 patients demonstrates superior weight reduction, fat mass loss, and visceral fat loss with the Allurion Smart Capsule combined with lifestyle intervention compared to lifestyle
11mo agoALURAllurion Announces Strategic Distribution Partnership with ProSurg Medical in Brazil to Pioneer New Approach Focused on Metabolically Healthy Weight LossBusiness WireAllurion Technologies, Inc. (NYSE:ALUR), a pioneer in metabolically healthy weight loss, today announced a strategic distribution partnership with ProSurg Medical, a leading Brazilian medical device company specializing
1y agoALURAllurion Passes Critical FDA Milestones, Enters Into Transaction to Exchange All Outstanding Debt That Would Result in the Company Being Debt-Free, and Announces a $5 Million Private Placement FinancingBusiness WirePassing of key audits with zero findings and completion of Day-100 meeting are significant milestones in the FDA PMA process as the Company enters final stages of FDA review process for its Allurion Smart
1y agoALURAllurion to Report Third Quarter 2025 Financial Results on November 12, 2025Business WireAllurion Technologies, Inc. ("Allurion" or the "Company") (NYSE:ALUR), a pioneer in metabolically healthy weight loss, today announced that it will report financial results for the third quarter 2025 on Wednesday,
1y agoALURAllurion Announces Landmark Peer-Reviewed Publication on Consecutive Use of the Allurion Smart Capsule Showing More Than 20% Weight LossBusiness WireMulticenter study across six countries demonstrates safety and efficacy of two consecutive treatments in adults with obesity Weight loss of greater than 20% on par with bariatric surgery and high dose GLP-1
1y agoALURAllurion to Participate in the ROTH 4th Annual Healthcare Opportunities ConferenceBusiness WireAllurion Technologies, Inc. (NYSE:ALUR), a pioneer in metabolically healthy weight loss, today announced its participation in the ROTH 4th Annual Healthcare Opportunities Conference, which will be held on October 9,
1y agoALURAllurion Technologies Inc. (ALUR) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
1y agoALURAllurion Reports Second Quarter 2025 Financial Results and Provides Business UpdateBusiness WireAllurion Technologies, Inc. (NYSE:ALUR), a pioneer in metabolically healthy weight loss, today announced its financial results for the second quarter and provided a business update. Recent Company Highlights and
1y agoALURAllurion to Report Second Quarter 2025 Financial Results on August 13, 2025Business WireAllurion Technologies, Inc. ("Allurion" or the "Company") (NYSE:ALUR), a pioneer in metabolically healthy weight loss, today announced that it will report financial results for the second quarter 2025 on Wednesday,
1y agoALURAllurion Announces New Strategic Direction With Increasing Focus on Low-Dose GLP-1 Combination Therapy, Muscle Mass Maintenance, and US Market EntryBusiness WireSigned term sheet with strategic partner to enhance distribution capabilities and R&D pipeline, including the potential joint development of a novel, GLP-1 drug-eluting balloon Submitted protocol to IRBs for
1y agoALURAllurion Announces New Publications on Long-Term Weight Loss Results with the Allurion ProgramBusiness WireIn 522 patients, average weight loss was approximately 32 pounds at balloon passage and 31 pounds 1 year later, equating to approximately 95% weight maintenance In 497 patients, average weight loss was 14.3% of total
1y agoALURAllurion Announces Strategic Distribution Partnership with Minogue Medical in Canada to Pioneer New Approach Focused on Metabolically Healthy Weight LossBusiness WireAllurion Technologies, Inc. (NYSE:ALUR), a pioneer in metabolically healthy weight loss, today announced a strategic distribution partnership with Minogue Medical Inc., a leading Canadian medical device company
1y agoALURAllurion Announces Submission of PMA to FDA and Additional Analyses From Pivotal AUDACITY Study That Meet Both EndpointsBusiness WireFourth and final module of the PMA submitted in June Supportive analyses included in final module of the PMA meet both of the pre-specified co-primary endpoints in the AUDACITY Study Allurion Technologies, Inc.
1y agoALURAllurion Announces Findings from New Studies on Muscle Mass Maintenance in Nearly 20,000 Patients and Four-Year Weight Loss Outcomes at the 2025 Annual Meeting of the ASMBSBusiness WireFindings from two abstracts presented at the American Society for Metabolic & Bariatric Surgery (ASMBS) 2025 Annual Meeting reinforce the role of the AI-powered Allurion Program in delivering metabolically healthy
1y agoALURAllurion to Present at Jefferies Global Healthcare ConferenceBusiness WireAllurion Technologies, Inc. ("Allurion" or the "Company") (NYSE:ALUR), a pioneer in metabolically healthy weight loss, today announced that Dr. Shantanu Gaur, Founder and Chief Executive Officer, will present at the
1y agoALURAllurion Presents Data on Increasing Muscle Mass and Decreasing Fat Mass in Patients Treated With the Allurion ProgramBusiness WireIn 1,962 patients treated in France with the Allurion Program, muscle mass as a percentage of total body weight increased, on average, by 6.6% and fat mass decreased, on average, by 11% Company announces that
1y agoALURAllurion Reports First Quarter 2025 Financial Results and Provides Business UpdateBusiness WireAllurion Technologies, Inc. (NYSE:ALUR) ("Allurion" or the "Company"), a pioneer in metabolically healthy weight loss, today announced its financial results for the first quarter and provided a business update. Recent
1y agoALURAllurion to Report First Quarter 2025 Financial Results on May 14, 2025Business WireAllurion Technologies, Inc. ("Allurion" or the "Company") (NYSE:ALUR), a company dedicated to ending obesity, today announced that it will report financial results for the first quarter 2025 on Wednesday, May 14, 2025.
1y agoALURAllurion Announces Postponement of Special Meeting of StockholdersBusiness WireMeeting to Now be Held on Thursday, April 10, 2025 at 12:00 pm Via Live Audio Webcast Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE:ALUR), a company dedicated to ending obesity, today announced that
1y agoALURAllurion Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business UpdateBusiness WireAllurion Technologies, Inc. (NYSE:ALUR) ("Allurion" or the "Company"), a company dedicated to ending obesity, today announced its financial results for the fourth quarter and full year ended December 31, 2024 and
1y agoALURAllurion Announces Initial Results on the Combination of the Allurion Program With Low-dose GLP-1 Therapy to Optimize Muscle Mass and GLP-1 AdherenceBusiness WireAverage Total Weight Loss of 20% With 15% Increase in Lean Body Mass After 8 Months of Combined Therapy Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE:ALUR), a company dedicated to ending obesity,
1y agoALURAllurion to Report Fourth Quarter 2024 Financial Results on March 26, 2025Business WireAllurion Technologies, Inc. ("Allurion" or the "Company") (NYSE:ALUR), a company dedicated to ending obesity, today announced that it will report financial results for the fourth quarter 2024 on Wednesday, March 26,
1y agoALURAllurion Announces Notification of Issuance of New U.S. Patents on Next-Generation Weight Loss Device for the Treatment of ObesityBusiness WirePatent portfolio now exceeds 60 issued patents globally Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE:ALUR), a company dedicated to ending obesity, today announced that it has received two Issue
1y agoALURAllurion to Participate in Upcoming Investor ConferencesBusiness WireAllurion Technologies, Inc. ("Allurion" or the "Company") (NYSE:ALUR), a company dedicated to ending obesity, today announced that it will be participating in two upcoming investor conferences. Dr. Shantanu Gaur,
1y agoALURAllurion Announces Closing of Offering and Concurrent Private Placement to Advance GLP-1 Clinical PipelineBusiness WireAllurion Technologies, Inc. ("Allurion" or the "Company") (NYSE:ALUR), a company dedicated to ending obesity, today announced that it has closed its previously announced registered direct offering with institutional
1y agoALURAllurion to Raise Approximately $6.1 Million of Gross Proceeds in Offering and Concurrent Private Placement to Advance GLP-1 Clinical PipelineBusiness WireAllurion Technologies, Inc. ("Allurion" or the "Company") (NYSE:ALUR), a company dedicated to ending obesity, today announced that it has entered into a definitive securities purchase agreement with certain
1y agoALURAllurion Announces Plans To Combine GLP-1 Therapy With The Allurion Balloon to Treat ObesityBusiness WireAllurion Technologies, Inc. ("Allurion" or the "Company") (NYSE:ALUR), a company dedicated to ending obesity, today announced its intention to initiate a clinical study on the combination of the Allurion Balloon with
1y agoALURAllurion Relaunches in FranceBusiness WireANSM, the French regulatory authority, clears Allurion to resume sales of the Allurion Balloon Company considering sites in France for clinical trial on combination therapy of Allurion Balloon and GLP-1s to prevent
1y agoALURAllurion to Raise Approximately $7.4 Million of Gross Proceeds in Offering Priced At-the-MarketBusiness WireAllurion Technologies, Inc. ("Allurion" or the "Company") (NYSE:ALUR), a company dedicated to ending obesity, today announced that it has entered into a definitive securities purchase agreement with certain
1y agoALURAllurion Announces Plans To Optimize Muscle Mass During GLP-1 Therapy In Combination With the Allurion ProgramBusiness WireAllurion Technologies, Inc. ("Allurion" or the "Company") (NYSE:ALUR), a company dedicated to ending obesity, today announced its intention to initiate a clinical study on the combination of the Allurion Program with
1y agoALURAllurion Announces Notification of Issuance of New U.S. Patent on Next-Generation Weight Loss Device for the Treatment of ObesityBusiness WireAllurion Technologies, Inc. ("Allurion" or the "Company") (NYSE:ALUR), a company dedicated to ending obesity, today announced that it has received an Issue Notification from the U.S. Patent and Trademark Office (USPTO)
1y agoALURAllurion Announces Private Placement of Common Stock and Preliminary Unaudited Financial Results for the Fourth Quarter and Fiscal Year 2024Business WireAllurion Technologies, Inc. ("Allurion" or the "Company") (NYSE:ALUR), a company dedicated to ending obesity, today announced that it has entered into a subscription agreement with funds affiliated with RTW Investments,
1y agoALURAllurion Announces Positive Topline Results From AUDACITY TrialBusiness WireAt 48 weeks, Allurion Balloon subjects had a greater than 50% responder rate and substantially greater weight loss than Control subjects Low rate of serious adverse events supports favorable safety profile of the
1y agoALURAllurion Technologies, Inc. Announces Reverse Stock SplitBusiness WireAllurion Technologies, Inc. (NYSE:ALUR) ("Allurion" or the "Company"), a company dedicated to ending obesity, today announced that its Board of Directors has determined to effect a one-for-twenty five reverse stock
1y agoALURAllurion Announces NYSE Acceptance of Plan to Regain Listing ComplianceBusiness WireAllurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced that it received an Acceptance Letter from the Listings Operations Committee of the New York Stock Exchange (the "NYSE")
1y agoALURAllurion Launches in the US with its First AI-Native Compounded GLP-1 ProgramBusiness WireAllurionMeds is designed to address a critical demand from patients: The Weight Must Stay Off Features Coach Iris, a first-of-its-kind conversational AI behavioral agent for weight loss and maintenance, trained using
1y agoALURAllurion Technologies Inc. (ALUR) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
1y agoALURAllurion Reports Third Quarter 2024 Financial Results and Provides Business UpdateBusiness WireAllurion Technologies, Inc. (NYSE:ALUR) ("Allurion" or the "Company"), a company dedicated to ending obesity, today announced its financial results for the third quarter ended September 30, 2024 and provided a business
2y agoALURAllurion Presents Data From Largest Ever Real-World Experience of 19,428 Patients at The Obesity Society's Annual ConferenceBusiness Wire19,428 patients treated with the Allurion Program across 72 countries lost an average of 12.2% of total body weight Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced the
2y agoALURAllurion to Report Third Quarter 2024 Financial Results on November 13, 2024Business WireAllurion Technologies, Inc. (NYSE:ALUR) ("Allurion" or the "Company"), a company dedicated to ending obesity, today announced that it will report financial results for the third quarter 2024 on Wednesday, November 13,
2y agoALURAllurion Announces Submission of First Three Modules of Premarket Approval Application to the U.S. Food and Drug Administration for the Allurion BalloonBusiness WireAllurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced the submission of the first three modules of its premarket approval application (PMA) to the U.S. Food and Drug
2y agoALURAllurion Announces Publication of New Data Demonstrating Muscle Mass Preservation in Patients Experiencing 15% Weight LossBusiness WireIn a study of 167 patients, average weight reduction was 15.7% at four months, 17.1% at six months, and 14.7% at one year Body fat percentage decreased at six months with no change in muscle mass Allurion
2y agoALURAllurion Announces Publication of Meta-Analysis Demonstrating the Safety and Effectiveness of the Allurion Program for Weight LossBusiness WireSystematic review of 11 studies involving 2,107 patients reports average weight reduction of 12.5% with significant improvements in metabolic health Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to